À̼®È¯ ¸íÀÇ

ÁøÇ༺ Á÷Àå¾Ï ȯÀÚÀÇ Á÷Àå º¸Á¸ Ä¡·á, ´ëÀå¾ÏÁ¶±â ¹ß°ß

À̼®È¯ ¸íÀÇ

  • ¼Ò ¼Ó
    °­µ¿°æÈñ´ëÇб³º´¿ø ¼ÒÈ­±â¿Ü°ú
  • Àü¹®ºÐ¾ß
    ´ëÀå¾Ï, Á÷Àå¾Ï, Ç×¹®Áúȯ, º¹°­°æ Á÷Àå¼ö¼ú, ·Îº¿¼ö¼ú

´ëÀå¾Ï, Á÷Àå¾Ï ºÐ¾ß¿¡¼­ ¸¹Àº °æÇè°ú ¼ö»ó °æ·ÂÀ» °¡Áø ÀÇ»çÀÌ´Ù. ÁÖ¿ä Áø·á ºÐ¾ß´Â ´ëÀå¾Ï, Á÷Àå¾Ï, º¹°­°æ¼ö¼ú, ·Îº¿¼ö¼úÀÌ´Ù.
1998³âºÎÅÍ º¹°­°æ ´ëÀå ÀýÁ¦¼úÀ» ½ÃÀÛÇß°í, Ãʱ⠴ëÀå¾ÏÀº ¹°·Ð ÁøÇ༺ ´ëÀå¾Ï±îÁö ´ÜÀϰø º¹°­°æ ¼ö¼úÀ» ¼±µµÇϰí ÀÖ´Ù. ¹Ì±¹ Ŭ¸®ºê·£µå Ŭ¸®´Ð ´ÜÀϰø º¹°­°æ Çмú´ëȸ¿¡¼­ ÃÖ¿ì¼ö Æ÷½ºÅÍ»óÀ» ¼ö»ó, 2015³â ¾Æ½Ã¾ÆÅÂÆò¾ç ´ëÀåÇ×¹®ÇÐȸ¿¡¼­ ´ÜÀϰø º¹°­°æ ¼ö¼ú¿¡ ´ëÇÑ ¿¬±¸ °á°ú¸¦ ¹ßÇ¥, 2019³â ¿À½ºÆ®¸®¾Æ ºó¿¡¼­ ¿­¸° À¯·´´ëÀåÇ×¹®ÇÐȸ Çмú´ëȸ¿¡¼­ New Trial Forum ºÎºÐ¿¡¼­ ¾Æ½Ã¾Æ±Ç À¯ÀÏ ÃÖ¿ì¼ö ¿¬±¸»óÀÎ ¡®The Best New Trial¡¯À» ¼ö»óÇß´Ù. À̼®È¯ ±³¼öÆÀÀÇ ±¹³» Á÷Àå¾Ï ¡®°­È­Ç×¾ÏÄ¡·á¡¯¿¬±¸·Î Çаè ÃÖ°í ¼öÁØÀÇ ±ÇÀ§¸¦ Áö´Ñ ¡®2022³â ¹Ì±¹´ëÀåÇ×¹®ÇÐȸ ±³°ú¼­¡¯ °³Á¤ÆÇ¿¡ ÀοëµÇ±âµµ Çß´Ù. ÁøÇ༺ Á÷Àå¾ÏÀÇ ¼ö¼ú Àü ¹æ»ç¼± Ä¡·á¿Í °­È­È­Çпä¹ýÀ» µµÀÔÇÏ¿©, ºñ¼ö¼ú Ä¡·á ¹æ¹ýÀ» ȯÀÚ¿¡°Ô Àû¿ë ÁßÀ̸ç, °ü·Ã ¿¬±¸µµ Ȱ¹ßÈ÷ ÁøÇàÇϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ¹Ú»ç
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ ¼®»ç
  • °æÈñ´ëÇб³ Àǰú´ëÇÐ Çлç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °­µ¿°æÈñ´ëÀǴ뺴¿ø ¿Ü°ú ±³¼ö
  • °­µ¿°æÈñ´ëÇб³º´¿ø ¿Ü°ú °úÀå ¿ªÀÓ
  • University of Minnesota research fellow
  • ÀÌÈ­¿©ÀÚ´ëÇб³ Á¶±³¼ö

¼ö»ó³»¿ª

Awards List
  • 2019 À¯·´´ëÀåÇ×¹®Çмú´ëȸ New Trial Forum ºÎºÐ 'The Best New Trial' ¼ö»ó

ÇÐȸȰµ¿

Academic activities
  • 2023 ~ ÇöÀç´ëÇѼö¼ú°¨¿°ÇÐȸ ȸÀå
  • 2020 ~ 2022´ëÇѳ»½Ã°æº¹°­°æ¿Ü°úÇÐȸ ÀÌ»çÀå
  • 2014 ~ 2020´ëÇѳ»½Ã°æº¹°­°æ¿Ü°úÇÐȸÁö (JMIS) ÆíÁýÀå
  • 2019 ~ 2021´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ÀÌ»çÀå
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Clinicopathological Outcomes in Patients With Locally Advanced Rectal Cancer Undergoing Preoperative Short-Versus Long-course Chemoradiotherapy With Delayed Surgery
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö In vivo (Athens, Greece). 2023;37(6):2768-2775
Á¦ ¸ñ ¼ö¼úºÎÀ§°¨¿° ¿¹¹æ ¹øµé Áß°³¿¡ °üÇÑ °íÂû
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Journal of Surgical Infection. 2023;8(2):40-50
Á¦ ¸ñ Total neoadjuvant therapy for rectal cancer: evidence and challenge
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö Annals of Coloproctolgy. 2023;39(4):301-306
Á¦ ¸ñ Impact of COVID-19 on the care of acute appendicitis: A single-center experience in Korea
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Annals of Surgical Treatment and Research. 2021;101(4):240-246
Á¦ ¸ñ Quality of life and patient satisfaction after single- and multiport laparoscopic surgery in colon cancer: a multicentre randomised controlled trial
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES. 2021;35(11):6278-6290
Á¦ ¸ñ Is Laparoscopic Complete Mesocolic Excision and Central Vascular Ligation Really Necessary for All Patients With Right-Sided Colon Cancer?
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Annals of Coloproctolgy. 2021;37(6):434-444
Á¦ ¸ñ Short-term Outcomes of Single-port Versus Multiport Laparoscopic Surgery for Colon Cancer: The SIMPLE Multicenter Randomized Clinical Trial
¹ßÇ¥³âµµ 2021 ¹ßÇ¥Áö Annals of surgery. 2021;273(2):217-223

¸íÀÇqna ¸íÀÇ QnA

Q °¡Àå °ü½É ÀÖ´Â ºÐ¾ß¿Í ¾÷ÀûÀÌ ÀÖ´Ù¸é ¾Ë·ÁÁÖ¼¼¿ä

ÁøÇ༺ Á÷Àå¾ÏÀÇ ¼ö¼ú Àü ¹æ»ç¼± Ä¡·á ¹× °­È­È­Çпä¹ýÀ» ºñ·ÔÇÑ Àüü ¼±Çà Ä¡·á¹ýÀ» ȯÀڵ鿡°Ô Àû¿ëÇÏ¿© Á÷Àå º¸Á¸ Ä¡·áÀÇ °¡´É¼ºÀ» Ȱ¹ßÈ÷ ¿¬±¸ ÁßÀÌ´Ù. 2017³â 1¿ùºÎÅÍ 2023³â 6¿ù±îÁö ÁøÇàÇÑ ±¹³» ÀÓ»ó ¿¬±¸ÀÇ Ã¥ÀÓÀÚ·Î ¿¬±¸ °á°ú¸¦ 2024³â Àü¹ÌÀÓ»ó¾ÏÇÐȸ ¹× À¯·´´ëÀåÇ×¹®ÇÐȸ¿¡¼­ ¹ßÇ¥ÇÏ¿´´Ù. ÁøÇ༺ Á÷Àå¾ÏÀÇ Àüü¼±ÇàÄ¡·á¹ýÀÇ °æÇèÀ» °¡Àå ¸¹ÀÌ º¸À¯ÇÑ ¿Ü°ú ÀÇ»çÀÌ´Ù.

Q ȯÀÚ Áø·á¿¡ ÀÖ¾î °¡Àå Áß¿äÇÏ°Ô »ý°¢ÇÏ´Â °¡Ä¡´Â?

ȯÀÚÀÇ »îÀÇ Áú°ú Ä¡·á ¼ºÀûÀ» ¸ðµÎ »ý°¢Çؼ­ °³°³ÀÎÀÇ È¯ÀÚ¿¡°Ô ƯȭµÈ Ä¡·á¹ýÀ» Á¦°øÇÒ ¼ö ÀÖ´Â Á¤¹Ð ÀÇÇÐÀÇ ½Ã´ë°¡ ½ÃÀ۵Ǿú½À´Ï´Ù. ÁúȯÀ» º¸´Â Àǻ簡 ¾Æ´Ñ ÀßȯÀ» °¡Áø ȯÀÚ¸¦ º¸´Â ÀÇ»ç·Î ±â¾ïµÇ±æ ¹Ù¶ø´Ï´Ù.

Q ȯÀڵ鿡°Ô ÀüÇÏ°í ½ÍÀº ¸»¾¸

´ëÀå¾ÏÀº ¿ÏÄ¡°¡ °¡´ÉÇÑ ¾ÏÀÔ´Ï´Ù. °ËÁõµÇÁö ¾ÊÀº ¹æ¹ý¿¡ ½Ã°£À» ³¶ºñÇÏÁö ¸»°í, ȯÀÚ¿¡°Ô ÃÖ¼±ÀÇ Ä¡·á ¹æÇâÀ» Á¦°øÇÏ´Â º´¿øÀ» ã¾Æ Ä¡·á¹ÞÀ¸½Ã±æ ±ÇÀ¯ÇÕ´Ï´Ù. 2018³â ¼¼°èÀûÀÎ ÀÇÇÐÀâÁöÀÎ ¶õ¼Â(Lacet)¿¡¼­ Çѱ¹Àº ´ëÀå, Á÷Àå¾Ï Ä¡·áÀ²ÀÌ ¼¼°è¿¡¼­ °¡Àå ÁÁÀº ³ª¶ó¶ó°í ¹ßÇ¥µÇ¾î ÀÖ½À´Ï´Ù. ÃÖ½ÅÀÇ, ÃÖ¼±ÀÇ Ä¡·á¸¦ Á¦°øÇÏ´Â ÀÇ·áÁøÀ» ¹Ï°í Ä¡·á¹ÞÀ¸½Ã±æ ¹Ù¶ø´Ï´Ù.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°­µ¿°æÈñ´ëÇб³º´¿ø

Á¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1577-5800
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°­µ¿°æÈñ´ëÇб³º´¿øÀº Àǰú, ÇÑÀǰú, Ä¡°ú´ëÇÐÀ» ¸ðµÎ º¸À¯ÇÑ º´¿øÀ¸·Î, 3°³ ´ëÇк´¿øÀÇ ¼öÁØ ³ôÀº ÀÇ·á¼­ºñ½º¸¦ ÇÑ ¹ø¿¡ ¹ÞÀ» ¼ö ÀÖ´Ù. ¿¬¸éÀû 24,000¿© Æò º»°ü Áö»ó 14Ãþ, º°°ü Áö»ó 4ÃþÀÇ 800º´»óÀ» °®Ãè´Ù. ³úÁúȯ¡¤°üÀý¡¤Ã´Ãß µî Áúȯ Áß½ÉÀ¸·Î ƯȭµÈ ÇùÁø ÀÇ·á
¼­ºñ½º¸¦ Á¦°øÇÏ´Â ÀÇ¡¤ÇÑ ÇùÁø¼¾ÅÍ, ȯÀÚ ¼¼°è ÃÖ°í ¼öÁØÀÇ Áø·á½Ã½ºÅÛÀ» °®Ãá Àǰú
´ëÇк´¿ø, ÇÑÀÇÇÐÀ» ¼±µµÇÏ´Â ÇÑ¹æ ºê·£µåÆÄÀ§ 1À§ ÇÑÀǰú´ëÇк´¿ø¿Í Àü¹®¼º°ú ÆíÀǼºÀ» °®Ãá ȯÀÚ¸¸Á· º´¿øÀÎ Ä¡°ú´ëÇк´¿øÀÌ ÃÖ»óÀÇ ÀÇ·á¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù.

°­µ¿°æÈñ´ëÇб³º´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã °­µ¿±¸ µ¿³²·Î 892

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä